martes, 10 de abril de 2018

Plasma DNA and Metastatic Castration-Resistant Prostate Cancer: The Odyssey to a Clinical Biomarker Test. - PubMed - NCBI

Plasma DNA and Metastatic Castration-Resistant Prostate Cancer: The Odyssey to a Clinical Biomarker Test. - PubMed - NCBI



 2018 Apr;8(4):392-394. doi: 10.1158/2159-8290.CD-18-0124.

Plasma DNA and Metastatic Castration-Resistant Prostate Cancer: The Odyssey to a Clinical Biomarker Test.

Abstract

Comprehensive plasma DNA analysis identifies clinically actionable genomic aberrations. Cancers harboring disruption of TP53 or BRCA2 or ATM detected in plasma have significantly worse outcomes on novel AR targeting. Cancer Discov; 8(4); 392-4. ©2018 AACR.See related article by Annala et al., p. 444.

PMID:
 
29610288
 
DOI:
 
10.1158/2159-8290.CD-18-0124

No hay comentarios:

Publicar un comentario